OUR PRODUCT IS A PLATFORM THERAPEUTIC MODALITY WITH THE POTENTIAL TO TREAT A BROAD RANGE OF DISEASES
Acute Kidney Injury
Sentien is preparing for the first clinical trial of SBI-101 in severe acute kidney injury (AKI). AKI is a sudden loss of kidney function and can lead to multi-organ failure, systemic inflammatory response syndrome (SIRS) and death. Patients diagnosed with severe AKI are placed on dialysis, require extensive stays in the ICU and have mortality rates of 50-70%. Those who survive the acute phase of injury are at significant risk of requiring a kidney transplant and/or life-long dialysis. Sentien’s technology has been tested in numerous preclinical models, and in each case, overall survival increased relative to controls.
Single factor medications have shown to be ineffective for AKI because they fail to address the multi-factorial pathophysiology of the disease. With dialysis as the only therapeutic option for these patients, there is an urgent need for a therapy that can simultaneously address the many complex disease processes associated with severe AKI, and can reduce the significant morbidity and mortality associated with this disease.
To treat AKI patients, SBI-101 integrates seamlessly into a continuous renal replacement therapy (CRRT) circuit and delivers MSC-secreted factors directly to the bloodstream of patients. This design provides AKI patients with both hemofiltration and active stem cell therapy in a single session and requires minimal changes to existing dialysis equipment and protocols for ICU staff.
Acute Liver Failure
According to the American Liver Foundation, 500,000 patients are admitted to hospitals each year with chronic liver disease, which is responsible for 42,000 deaths per year in the US alone. Acute episodes are exacerbated by the rise in chronic disease.
ALF is another complex disease that requires a broad-spectrum therapy. Since a small amount of liver mass has the potential to regenerate if allowed sufficient time to recover, there is a need for a treatment that protects further liver injury and promotes tissue repair/regeneration. Our technology supplements blood with MSC-derived secretions, thereby providing the liver tissue with cytoprotective and regenerative factors that can stimulate recovery. Animal studies have shown as much as a 500% improvement in survival, so we hope that this increased survival benefit will translate to the clinic.
Since dialysis is an established treatment for ALF, SBI-101 could be integrated seamlessly into the existing dialysis infrastructure.
Acute Myocardial Infarction
About 650,000 patients per year in the US suffer a myocardial infarction for the first time. Myocardial infarction (MI) can lead to a complex injury pattern as a consequence of the primary ischemic damage to the heart.
Many patients who suffer an MI undergo coronary artery bypass surgery, which is beneficial to the vast majority of patients, but is associated with neurocognitive dysfunction in about 30% of patients, and further myocardial injury, renal failure and other organ injury in a large proportion of these patients. A multi-pronged approach that can protect the heart and end-organ injury can lead to a significant improvement in morbidity/mortality after a heart attack. Our technology seeks to treat patients during cardiac care post-MI by supplementing patient blood with MSC-derived secretions.
Single compound therapy has had limited clinical success in treating the complications of heart attacks. Treatment with SBI-101 offers a broader spectrum approach to treating a complex injury.